Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2015

Conditions
Thyroid Associated OphthalmopathiesGraves´ OphthalmopathyThyroid Eye Disease
Interventions
DRUG

Tocilizumab (RoActemra®)

Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.

DRUG

Sterile 0.9% Sodium Chloride

Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.

Trial Locations (9)

15706

Hospital Clínico de Santiago, Santiago de Compostela

Unknown

Hospital Santa Creu i Sant Pau, Barcelona

Hospital Clínico San Carlos, Madrid

Hospital Universitario Ramón y Cajal, Madrid

Centro Oftalmológico Moreiras, Santiago de Compostela

Hospital Universitario Virgen del Rocío, Seville

Hospital Universitario Virgen Macarena, Seville

Hospital Universitario La Fe, Valencia

Hospital Clínico Universitario Lozano Blesa, Zaragoza

All Listed Sponsors
collaborator

Fundación Ramón Domínguez

OTHER

lead

Hospital Clinico Universitario de Santiago

OTHER

NCT01297699 - Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) | Biotech Hunter | Biotech Hunter